Enhanced Expression of CD13 in Vessels of Inflammatory and Neoplastic Tissues
Enhanced Expression of CD13 in Vessels of Inflammatory and Neoplastic Tissues
复制标题
CD13 在炎症和肿瘤组织血管中的表达增强
DOI：
10.1369/jhc.2010.956644
复制
发表时间：
2011-01-01
影响因子：
3.2
通讯作者：
Rizzardi, Gian-Paolo
中科院分区：
文献类型：
--
作者：
Di Matteo, Paola;Arrigoni, Gian Luigi;Rizzardi, Gian-Paolo
氨基肽酶- n （CD13）是肿瘤血管靶向药物的重要靶点。采用免疫组化方法，用3种抗cd13单克隆抗体（WM15、3D8、BF10）在58例正常、32例炎症和149例肿瘤组织中表达cd13。这三种抗体在大多数肿瘤组织中染色血管，有趣的是它们的模式不同。事实上，WM15几乎染色了所有肿瘤内和肿瘤周围的毛细血管，仅染色了部分大血管，而BF10和3D8与动脉和小静脉反应，与毛细血管反应的程度较小。这些抗体也在大约一半的肿瘤组织中染色。在炎性病变中，这三种抗体会染色血管和间质，而在正常组织中，它们只会染色一小部分血管。最后，这三种抗体对正常结肠内皮细胞染色失败，而对活化的人脐静脉内皮细胞和结肠腺癌血管内皮细胞有反应。总的来说，WM15是血管生成肿瘤血管的最特异性抗体，这表明它可能是检测与肿瘤血管相关的CD13形式的良好工具。这一发现可能与cd13介导的血管靶向治疗有关。（中国生物医学工程学报，2011）
Aminopeptidase-N (CD13) is an important target of tumor vasculature-targeting drugs. The authors investigated its expression by immunohistochemistry with three anti-CD13 monoclonal antibodies (WM15, 3D8, and BF10) in normal and pathological human tissues, including 58 normal, 32 inflammatory, and 149 tumor tissue specimens. The three antibodies stained vessels in most neoplastic tissues, interestingly with different patterns. As a matter of fact, WM15 stained almost all intratumor and peritumor capillaries and only partially large vessels, whereas BF10 and 3D8 reacted with arteries and venules and to a lesser extent with capillaries. These antibodies also stained the stroma in about half of neoplastic tissues. In inflammatory lesions, the three antibodies stained vessels and stroma, whereas in normal tissues, they stained a small percentage of blood vessels. Finally, the three antibodies failed to stain endothelial cells of normal colon, whereas they reacted with activated human umbilical vein endothelial cells and with endothelial cells of colon adenocarcinoma vessels. Overall, WM15 was the most specific antibody for angiogenic tumor vessels, suggesting that it may be a good tool for detecting the CD13 form associated with the tumor vasculature. This finding may be relevant for CD13-mediated vascular targeting therapies. (J Histochem Cytochem 59:47-59, 2011)